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a b s t r a c t
Recent studies demonstrated that soluble urokinase plasminogen activator receptor (suPAR) is a valuable
marker in the recognition of an inﬂammatory response. Ongoing inﬂammation leads to elevated plasma
suPAR levels. We aimed to characterize plasma suPAR levels in ankylosing spondylitis (AS) patients com-
pared to healthy individuals in order to reveal if suPAR could be used as a clinical marker of inﬂammation
in AS. We measured plasma suPAR and C-reactive protein (CRP) levels as well as erythrocyte sedimenta-
tion rate (ESR) in 33 AS patients at various stages of disease duration and activity and 29 healthy controls.
CRP and ESR values were higher in AS patients than in healthy individuals, while suPAR values were com-
parable (median [interquartile range]: 2.97 [2.57–3.80] ng/mL vs. 2.80 [2.06–3.42] ng/mL, P>0.05). In AS
patients, a correlation was detected between BASDAI scores and CRP as well as ESR values but not suPAR
levels (P=0.0005, r=0.57 and P=0.01, r=0.43, respectively). Unlike in many other inﬂammatory condi-
tions, plasma suPAR levels do not reﬂect inﬂammation in AS. To assess the inﬂammatory status in AS, ESR
and particularly CRP values are still more appropriate clinical markers. In line with earlier ﬁndings, our
results indicate that, unlike suPAR, both of these markers are positively correlated with disease activity
in AS.
© 2012 Société franc¸aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.. Introduction
Urokinase-type plasminogen activator receptor (uPAR) is
xpressed on various cell types, including immune, smooth muscle
nd endothelial cells [1]. This membrane protein may be released
rom the cell surface, thus forming a free soluble receptor, solu-
le urokinase plasminogen activator receptor (suPAR). suPAR is
etectable in low, but practically constant concentrations inplasma
f healthy individuals [2]. However, recent studies demonstrated
hat suPAR is a valuable marker in the recognition of an inﬂam-
atory response. Increased activation of the immune system and
ngoing inﬂammation lead to elevated plasma suPAR levels, as
eported in conditions such as infectious [3], autoimmune [4],
eoplastic [2] and pregnancy-related [5] diseases. Furthermore,
levated plasma suPAR levels were associated with an increased
isk for low-grade inﬂammation, which is a contributing factor
o the development of cardiovascular disease and type 2 diabetes
ellitus, and is associated with higher mortality [6]. Importantly,
∗ Corresponding author. Tel.: +36 20 43 67 181; fax: +36 13 13 82 12.
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297-319X/$ – see front matter © 2012 Société franc¸aise de rhumatologie. Published by E
oi:10.1016/j.jbspin.2012.06.023higher levels of suPAR were proportional to a worse prognosis in
the above conditions [3,6].
suPAR’s high stability in plasma samples makes it an ideal can-
didate as a potential clinical marker. In contrast with C-reactive
protein (CRP), suPAR levels are stable throughout the day in healthy
individuals, independently whether the subject is fasting or not.
Even repeated freeze-thaw procedures of plasma samples do not
affect suPAR concentrations [7].
Ankylosing spondylitis (AS) is an immune-mediated rheumatic
disease characterized by chronic inﬂammation. The autoimmune
reaction principally affects the axial and sacroiliac joints in AS.
As the disease progresses, the chronic inﬂammation of the spine
(spondylitis) causes extra bone formation and eventually leads
to the fusion of the vertebrae (ankylosis). In later stages of the
disease, systemic autoimmune reactions can result in signiﬁcant
target organ damage, causing peripheral arthritis, enthesitis, and
extra-articular manifestations such as inﬂammation in the eye, the
gastrointestinal tract, and theheart [8]. Therefore, early and reliable
detection and monitoring of inﬂammation is of utmost importance
in the management of AS.
In this study we aimed to characterize plasma suPAR levels in
AS patients compared to healthy individuals in order to reveal if
suPAR could be used as a clinical marker of inﬂammation in AS.
lsevier Masson SAS. All rights reserved.
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Table 1
Clinical characteristics of healthy individuals and AS patients.
Characteristics Healthy individuals
n=29
AS patients
n=33
Age (years) 55 [46–69] 41a [35–45]
Gender (male/female) 10/18 24/9
AS duration (years) – 10 [7–12]
BASDAI – 5.49 [2.40–6.79]
No. of patients receiving sulfasalazine (%) – 10 (30.3%)
No. of patients receiving anti-TNF therapy (%) – 15 (45.5%)
No. of patients with active disease before receiving anti-TNF therapy (%) – 16 (48.5%)
No. of patients with eye symptoms in history (%) – 13 (39.4%)
No. of patients with peripheral joint symptoms in history (%) – 18 (54.5%)
suPAR (ng/mL) 2.80 [2.06–3.42] 2.97 [2.57–3.80]
CRP (mg/L) 2.70 [BLD–4.15] 10.00a [2.75–25.80]
ESR (mm/h) 10 [7–14] 17a [10–33]
Data are expressed as median [interquartile range]. AS: ankylosing spondylarthritis; BASDAI: Bath ankylosing spondylarthritis disease activity index; BLD: below the level
o soluble urokinase plasminogen activator receptor.
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Table 2
suPAR levels in different subgroups of AS patients.
Study group suPAR (ng/mL)
Healthy individuals 2.80 [2.06–3.42]
AS patients according to BASDAI index
≤4 (42.4%) 3.02 [2.66–3.46]
>4 (57.6%) 2.97 [2.38–3.84]
AS patients according to sulfasalazine treatment
Yes (30.3%) 2.97 [2.60–3.55]
No (69.7%) 3.04 [2.35–3.94]
AS patients according to anti-TNF therapy
Yes (45.5%) 2.92 [2.66–3.75]
No (54.5%) 2.99 [2.34–3.92]
AS patients according to disease activity before receiving anti-TNF therapy
Active disease (48.5%) 2.99 [2.44–3.82]
Inactive disease (51.5%) 2.92 [2.60–3.59]
AS patients according to eye symptoms in history
Yes (39.4%) 2.75 [2.31–3.54]
No (60.6%) 3.07 [2.66–3.82]
AS patients according to peripheral joint symptoms in history
Yes (54.5%) 3.02 [2.63–3.92]
No (45.5%) 2.97 [2.44–3.55]
AS patients according to CRP values
≤5 (39.4%) 2.66 [2.57–3.03]
>5 (60.6%) 3.22 [2.52–4.20]
AS patients according to ESR values
≤20 (66.7%) 2.68 [2.43–3.12]
>20 (33.3%) 4.16a,b [3.20–4.29]
Data are expressed as median [interquartile range]. AS: ankylosing spondylarthri-
tis; BASDAI: Bath ankylosing spondylarthritis disease activity index; CRP: C-reactive
protein; ESR: erythrocyte sedimentation rate; suPAR: soluble urokinase plasmino-
gen activator receptor; TNF: tumor necrosis factor.
a P<0.05 vs. healthy individuals.f detection; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; suPAR:
a P<0.05 vs. healthy individuals.
. Case report
Weenrolled 29healthy individuals and33ASpatients at various
tages of disease duration and activity. Clinical parameters of study
articipants are summarized in Table 1. ASpatientswerediagnosed
nd classiﬁed according to the modiﬁed New York criteria [9]. All
S patients were diagnosed at least two years before sampling.
he median of AS duration was 10 years in the patient group, and
he median of Bath ankylosing spondylitis disease activity index
BASDAI) was 5.49, corresponding to active disease. BASDAI scores
ere calculated at the time of sampling. Ten of 33 patients received
ulfasalazine treatment, while 15 of 33 AS patients received anti-
NF therapy. Healthy controls had a negative history of rheumatic
ymptoms and negative status upon detailed physical and labora-
ory examination. Written informed consent was obtained from all
ubjects, and our studywas reviewed and approved by an indepen-
ent ethical committee of the institution. Laboratory studies and
nterpretationswere performed on coded samples lacking personal
nd diagnostic identiﬁers. The study was adhered to the tenets of
he most recent revision of the Declaration of Helsinki.
Plasma was isolated from EDTA anticoagulated fasting blood
amples and stored at −80 ◦C until measurement. Plasma suPAR
oncentrations were measured with the suPARnostic Flex ELISA
ssay (ViroGates A/S, Birkerød, Denmark). CRP levels were
easured using a Roche Hitachi 912 instrument with Roche Tina-
uant CRP immuno-turbidimetric assay (Roche Diagnostics GmbH,
annheim, Germany). For the determination of erythrocyte sed-
mentation rate (ESR), the Westergren method was performed
ccording to ICSH speciﬁcations [10] on undiluted EDTA anti-
oagulated blood samples using glass pipettes (Greiner Bio-One,
remsmuenster, Austria). During sedimentation, the pipettes were
ounted vertically on appropriate supporting racks and kept at
oom temperature, which never exceeded 25 ◦C.
Data are expressed as median [interquartile range]. CRP values
elow the level of detection were regarded as “1”. Comparisons
etween healthy individuals and AS patients were made with
ann-Whitney tests. In case of comparisons between healthy
ontrols andAS patient subgroups, the Kruskal-Wallis testwas per-
ormed. To test the correlation between suPAR levels and other
nvestigated parameters, Spearman testswere used. To exclude the
otential independent effect of sulfasalazine and anti-TNF therapy
n the assessed factors, multiple regression analysis was used. P
alues less than 0.05 were considered signiﬁcant. Statistics were
alculated using the SPSS software (version 20.0, SPSS, Inc. Chicago,
L, USA).
CRP and ESR values were higher in AS patients than in healthy
ndividuals, while suPAR values were comparable (Table 1). Whenb P<0.05 vs. AS patients according to ESR value less or equal to 20.
suPAR levels were analyzed according to different subgroups of AS
patients (according to BASDAI scores, sulfasalazine and anti-TNF
therapy, disease activity before receiving anti-TNF therapy, eye and
peripheral joint symptoms in patient history, CRP and ESR values),
we found that AS patients with an ESR value greater than 20mm/h
had elevated suPAR levels compared to AS patients with an ESR
value less or equal to 20mm/h and healthy controls (Table 2).
Correlation analyses revealed a correlation between suPAR and
CRP as well as suPAR and ESR values in AS patients (P=0.01, r=0.45
and P=0.01, r=0.42, respectively, Fig. 1A and B). Furthermore,
suPAR values were correlated to CRP values in healthy individuals
(P=0.02, r=0.32, Fig. 1C). In AS patients, a correlation was detected
betweenBASDAI scores andCRPaswell as ESRvalues but not suPAR
levels (P=0.0005, r=0.57 and P=0.01, r=0.43, respectively, Fig. 1D
and 1E).
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Fig. 1. Correlations between soluble urokinase plasminogen activator receptor
(suPAR), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in anky-
losing spondylitis (AS) patients and healthy individuals and between inﬂammatory
markers and Bath ankylosing spondylitis disease activity index (BASDAI) scores in
AS patients. A. suPAR levels were correlated with CRP levels in AS patients. B. suPAR
levels were correlated with ESR values in AS patients. C. suPAR levels were cor-
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[elated with CRP levels in healthy individuals. D. CRP levels were correlated with
ASDAI scores in AS patients. E. ESR values were correlated with BASDAI scores in
S patients.
. Discussion
Several studies and clinical observations support the notion that
S is a systemic immune-mediated inﬂammatorydisease. Lympho-
yte subgroups in peripheral blood of AS patients show a number
f alterations in comparison with healthy subjects. For instance,
ncreased numbers of pro-inﬂammatory circulating Th17 cells [11]
ere reported in AS. On the other hand, regulatory T cells, major
uppressors of pro-inﬂammatory T lymphocytes exhibit lower fre-
uency in the blood of AS patients [12]. Recently, we reported that
ot only the prevalence, but also the functional properties (such as
alcium inﬂux and nitric oxide production) of peripheral lympho-
ytes are altered in AS [11].
To our best knowledge, AS is the ﬁrst inﬂammatory disorder
n which plasma suPAR levels do not indicate the ongoing inﬂam-
ation. Our pilot study does not provide an explanation for this
henomenon. Theoretically, itmight be due to the nature of inﬂam-
ation in this disease. In AS, inﬂammation occurs preferentially on
local level, in the vertebrae, and systemic manifestations occur
nly at later stages of the disease and are not necessarily severe.
While numerous studies described suPAR as a valuable marker
f inﬂammation, our present results do not support its usefulness
n the assessment of inﬂammation in AS. Although suPAR corre-
atedwith both CRP and ESR values, it failed to indicate the ongoing
nﬂammation in AS on its own. Furthermore, we were unable to
emonstrate a correlation between suPAR levels and disease activ-
ty (BASDAI scores, or other factors indicating disease severity, such
s eye or peripheral symptoms in patient history) in AS.
Of note, in our study, BASDAI scores showed a positive corre-
ation with both CRP and, to a lower extent, with ESR values. This
s in line with previous studies in AS. Yildirim et al. observed a
ositive correlation between CRP and BASDAI (P<0.05, r=0.556).
hey found, however, no correlation between BASDAI and other
cute phase reactants, including ESR, haptoglobin, and beta-2-
icroglobulin [13]. Likewise our results, their data suggest that CRP
s a better marker of disease activity than ESR. However, in another
tudy, the authors concluded that neither CRP nor ESR is superior
o assess disease activity in AS [14].
[ine 80 (2013) 96–98
Similarly to AS, RA is an immune-mediated inﬂammatory joint
disease. While AS has a predilection for axial joints, RA tar-
gets peripheral joints. Furthermore, autoantibody formation is the
immunological hallmark of RA, whereas AS is notable for being a
seronegativedisease. Contrastingour results inAS, in a studybySlot
et al., increased suPAR concentrations were found in plasma of RA
patients compared to healthy controls. Furthermore, suPAR in RA
was positively correlated to CRP and ESR values and the number of
swollen joints. The authors concluded that an elevated suPAR value
is a good indicator of erosive activity in RA [15]. This is in contrast
with our present observation in AS of comparable suPAR plasma
concentrations to healthy individuals.
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